Sugi Predict

Sugi Predict / Targets / MAP3K9

MAP3K9

Mitogen-activated protein kinase kinase kinase 9 · P80192 · MAP3K9 on Sugi Atlas →

14,245 patent compounds predicted against MAP3K9, 10,690 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
K-252A K-252A (SCHEMBL968886) 1.00 5/20
SCHEMBL484701 SCHEMBL484701 0.55 4/20
SCHEMBL1340714 SCHEMBL1340714 0.52 3/20
SCHEMBL573921 SCHEMBL573921 0.49 3/20
SCHEMBL31684 SCHEMBL31684 0.48 3/20
SCHEMBL783085 SCHEMBL783085 0.48 3/20
SCHEMBL260885 SCHEMBL260885 0.42 3/20
SCHEMBL574118 SCHEMBL574118 0.39 3/20
Lestaurtinib Lestaurtinib (SCHEMBL730955) 1.00 2/20
SCHEMBL868254 SCHEMBL868254 1.00 2/20
SCHEMBL869189 SCHEMBL869189 0.82 2/20
SCHEMBL870488 SCHEMBL870488 0.81 2/20
SCHEMBL868474 SCHEMBL868474 0.80 2/20
SCHEMBL869284 SCHEMBL869284 0.80 2/20
SCHEMBL1182226 SCHEMBL1182226 0.80 2/20
SCHEMBL869982 SCHEMBL869982 0.78 2/20
SCHEMBL868757 SCHEMBL868757 0.77 2/20
SCHEMBL868295 SCHEMBL868295 0.77 2/20
SCHEMBL869006 SCHEMBL869006 0.77 2/20
SCHEMBL868935 SCHEMBL868935 0.75 2/20

Clinical trials — most relevant to MAP3K9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Study of ASTX029 in Subjects With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP3K9 binder may also engage these)

ProteinNameSimilarity
Q3U1V8 — 1.000 Q3U1V8 →
D3ZG83 — 1.000 D3ZG83 →
O70405 — 0.999 O70405 →
Q66L42 — 0.998 Q66L42 →
Q8R0S2 — 0.997 Q8R0S2 →
Q68UT7 — 0.997 Q68UT7 →
Q6DN90 — 0.997 Q6DN90 →
Q8VDG6 — 0.997 Q8VDG6 →
MAP3K21 Mitogen-activated protein kinase kinase kinase 21 0.996 landscape →
Q4JIM5 — 0.996 Q4JIM5 →
Q3ULB5 — 0.996 Q3ULB5 →
Q6P1I6 — 0.996 Q6P1I6 →
Q7T2V3 — 0.996 Q7T2V3 →
Q9Y2H5 — 0.995 Q9Y2H5 →
O54967 — 0.995 O54967 →
Q76G19 — 0.995 Q76G19 →
E9Q9W7 — 0.995 E9Q9W7 →
KSR2 Kinase suppressor of Ras 2 0.995 landscape →
PLEKHG3 Pleckstrin homology domain-containing family G member 3 0.995 landscape →
Q60610 — 0.995 Q60610 →
Q60700 — 0.995 Q60700 →
Q9QY01 — 0.995 Q9QY01 →
Q61097 — 0.995 Q61097 →
Q3UJB9 — 0.995 Q3UJB9 →
KSR1 Kinase suppressor of Ras 1 0.994 landscape →
Q9H5P4 — 0.994 Q9H5P4 →
O94885 — 0.994 O94885 →
Q9H329 — 0.994 Q9H329 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.994 landscape →
Q80Z38 — 0.994 Q80Z38 →